Man Group plc Makes New $9.40 Million Investment in Azenta, Inc. $AZTA

Man Group plc purchased a new stake in Azenta, Inc. (NASDAQ:AZTA) in the second quarter, HoldingsChannel reports. The institutional investor purchased 368,419 shares of the company’s stock, valued at approximately $9,402,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of AZTA. Osaic Holdings Inc. increased its stake in shares of Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after purchasing an additional 385 shares during the last quarter. CWM LLC lifted its stake in Azenta by 27.3% in the 4th quarter. CWM LLC now owns 1,822 shares of the company’s stock valued at $61,000 after purchasing an additional 391 shares during the last quarter. Empowered Funds LLC lifted its stake in Azenta by 10.5% in the 1st quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock valued at $225,000 after purchasing an additional 618 shares during the last quarter. Neuberger Berman Group LLC grew its holdings in Azenta by 8.9% during the fourth quarter. Neuberger Berman Group LLC now owns 8,379 shares of the company’s stock worth $279,000 after purchasing an additional 684 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Azenta by 0.8% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 82,534 shares of the company’s stock worth $2,335,000 after purchasing an additional 686 shares during the period. Institutional investors own 99.08% of the company’s stock.

Azenta Stock Down 2.0%

Shares of NASDAQ:AZTA opened at $32.95 on Friday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The business has a 50 day moving average of $28.93 and a 200-day moving average of $25.20. The stock has a market cap of $1.44 billion, a PE ratio of -11.94 and a beta of 1.37.

Azenta (NASDAQ:AZTA) last announced its earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. The company had revenue of $161.18 million for the quarter, compared to analyst estimates of $149.31 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.

Analyst Ratings Changes

AZTA has been the topic of a number of recent analyst reports. Needham & Company LLC boosted their price target on Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Azenta currently has a consensus rating of “Hold” and an average price target of $41.20.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.